Benefits
Improved gait speed and physical function in older adults
Sekhar 2022 (PMID 35975308, J Gerontol A Biol Sci Med Sci) RCT in 24 older adults (mean age 71y) over 16 weeks showed GlyNAC supplementation INCREASED gait speed by 19% and improved physical function vs placebo (alanine isonitrogenous control). Improved muscle strength and exercise capacity. Notable for translating biochemical changes (glutathione restoration) to FUNCTIONAL outcomes that matter for healthspan.
Restored intracellular glutathione (red cells, muscle)
Sekhar 2022 demonstrated GlyNAC supplementation RESTORED intracellular GLUTATHIONE to youthful levels in older adults. Older adults at baseline had severe GSH deficiency (red cells, muscle); GlyNAC normalized to levels of young adult controls (mean age 25y). Biomarker change is mechanistic foundation for downstream functional improvements.
Reduced oxidative stress (TBARS -80%)
Sekhar trial documented 80% reduction in TBARS (thiobarbituric acid reactive substances — marker of lipid peroxidation/oxidative stress). Other oxidative stress markers (F2-isoprostanes) similarly improved. Magnitude of effect is unusual for nutritional intervention — reflects glutathione's central role in cellular antioxidant defense.
Improved insulin resistance (HOMA-IR -68%)
Sekhar 2022 showed 68% reduction in HOMA-IR (homeostatic model assessment of insulin resistance) — substantial improvement in glucose metabolism. Mechanism via mitochondrial fatty acid oxidation restoration and reduced oxidative stress impacts on insulin signaling. Important for metabolic health in aging.
Reduced inflammation (IL-6 -83%, TNF-α -58%)
Sekhar 2022 documented dramatic reductions in inflammatory cytokines: IL-6 down 83%, TNF-α down 58%. Magnitude is substantial — comparable to some prescription anti-inflammatory drugs. Sekhar 2024 follow-up (PMC11688924) showed GlyNAC reduces postprandial inflammation and oxidative stress after carbohydrate meals — important for daily exposure to dietary stressors.
Aging hallmarks improvement (multiple)
Sekhar 2022 measured multiple 'aging hallmarks' including mitochondrial dysfunction, mitophagy, inflammation, insulin resistance, endothelial dysfunction, body composition. Multiple hallmarks improved with GlyNAC supplementation. While specific magnitude varies by hallmark, the multi-mechanism improvement is unusual — most aging interventions affect 1-2 hallmarks. Suggests fundamental biochemical correction (glutathione deficiency) underlies multiple aging features.
Mechanism of action
Glutathione synthesis support — Sekhar's central hypothesis
Glutathione (γ-glutamyl-cysteinyl-glycine) requires three amino acids: glutamate, cysteine, glycine. CYSTEINE (delivered as NAC for stability and bioavailability) and GLYCINE are the rate-limiting precursors in older adults. Sekhar's research showed older adults have severe GSH deficiency NOT primarily due to enzymatic problems but due to PRECURSOR DEFICIENCY. Providing glycine + NAC restores GSH synthesis to youthful levels.
Mitochondrial function restoration
Glutathione is critical for mitochondrial function: protects mtDNA from ROS damage, maintains complex I activity, supports mitophagy (clearance of damaged mitochondria). Restored GSH improves mitochondrial fatty-acid oxidation (MFO) and ATP production. Mechanism for energy/strength improvements observed in trials.
Reduced oxidative damage to proteins, lipids, DNA
Glutathione directly scavenges ROS and supports glutathione peroxidase (GPx) activity. Reduces oxidative damage to membrane lipids (lipid peroxidation, TBARS), proteins (carbonylation), and DNA (8-oxo-dG). Mechanism for multiple downstream functional benefits.
NF-κB inhibition and inflammatory cytokine reduction
Oxidative stress activates NF-κB. Restoring glutathione/redox balance reduces NF-κB activation, decreasing IL-6, TNF-α, IL-1β. Mechanism for the dramatic anti-inflammatory effects observed in Sekhar trials — particularly relevant to 'inflammaging' in older adults.
Glycine independent benefits (sleep, GABA-glycine receptor)
GLYCINE has independent effects beyond glutathione synthesis: NMDA co-agonist, glycine receptor activity in CNS (sleep quality support, neuroprotection), substrate for collagen and creatine synthesis. Some clinical effects of GlyNAC may reflect glycine-specific benefits separate from glutathione restoration.
Clinical trials
Randomized double-blind placebo-controlled trial (Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV 2022, J Gerontol A Biol Sci Med Sci 78(1):75-89, doi:10.1093/gerona/glac135, PMID 35975308).
24 older adults (mean age 71y) randomized to GlyNAC (glycine 1.33 mmol/kg/d + NAC 0.83 mmol/kg/d) or isonitrogenous placebo (alanine) for 16 weeks. 12 young adults (mean age 25y) received GlyNAC for 2 weeks as comparison. Measurements: intracellular GSH, oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function, physical function, body composition, aging hallmarks.
Older adults at BASELINE had: severe GSH deficiency (red cells and muscle vs young adults), mitochondrial dysfunction, elevated oxidative stress (TBARS, F2-isoprostanes), reduced gait speed and exercise capacity, elevated waist circumference, insulin resistance, endothelial dysfunction. GlyNAC SUPPLEMENTATION RESULTS: restored GSH to youthful levels, improved mitochondrial fatty-acid oxidation, REDUCED TBARS by 80%, IL-6 by 83%, TNF-α by 58%, HOMA-IR by 68%; INCREASED gait speed by 19% and improved physical function. Multiple aging hallmarks improved. No significant adverse effects. Foundational pivotal RCT for GlyNAC supplementation in aging.
Postprandial RCT (Sekhar et al. 2024, follow-up gerontology research). PMC11688924.
20 older adults and 10 young adults given 75 g oral glucose test meal with assessment of 2-hour postprandial change in TBARS and IL-6. Repeated and compared after subjects received their assigned supplements (GlyNAC vs placebo).
BASELINE: older adults had significantly higher 2-hour postprandial increases in oxidative stress and inflammation vs young adults (TBARS: YA 0.02 vs OA 1.09, p=0.03; IL-6: YA 0.03 vs OA 0.52, p<0.001). After GlyNAC supplementation: protected older adults from glucose-meal-driven oxidative stress and inflammation rises. Important real-world finding — GlyNAC provides protection against daily dietary oxidative-inflammatory challenges, not just baseline biomarker correction.
Multiple smaller pilot studies preceding the 2022 RCT (Sekhar lab, Baylor College of Medicine). Including studies in HIV patients with premature aging, animal models, and metabolic syndrome contexts.
Various smaller cohorts including aged mice, HIV-infected adults with premature aging features, and pilot human studies.
Established GlyNAC effects on glutathione restoration, mitochondrial function, oxidative stress, and metabolic markers in multiple populations and species. Animal studies showed GlyNAC improved age-related deficits in aged mice including GSH, MFO, insulin resistance. Foundation for the pivotal 2022 RCT that translated preclinical findings to randomized human evidence.
About this ingredient
GlyNAC is a defined combination of GLYCINE (the simplest amino acid; ~100 mg/kg/day in studied protocol) and N-ACETYLCYSTEINE (NAC; ~135 mg/kg/day) developed and studied primarily by Dr. Rajagopal Sekhar at Baylor College of Medicine over ~20 years of translational research. Glycine and NAC together provide the rate-limiting precursors for glutathione (GSH = γ-L-glutamyl-L-cysteinyl-glycine) — the body's main intracellular antioxidant.
CYSTEINE is delivered as NAC because: (1) free cysteine is unstable and rapidly oxidized in solution, (2) NAC is well-absorbed orally and de-acetylated in cells to provide cysteine, (3) NAC has decades of clinical safety as FDA-approved drug for acetaminophen overdose. GLYCINE is delivered as free amino acid — sweet-tasting, water-soluble, safe at high doses. Sekhar's research identified that AGING IS ASSOCIATED WITH GSH DEFICIENCY in older adults (red cells, muscle), and that this deficiency is PRECURSOR-LIMITED rather than enzymatically limited.
Providing both glycine and cysteine (as NAC) restores GSH synthesis to youthful levels. The downstream effects — improved mitochondrial function, reduced oxidative stress, improved insulin sensitivity, reduced inflammation, improved physical function — flow from this central biochemical correction. EVIDENCE: 3/5 reflects: (1) Sekhar 2022 PMID 35975308 PIVOTAL 16-week RCT in 24 older adults with substantial improvements across multiple endpoints, (2) Sekhar 2024 PMC11688924 postprandial protection RCT, (3) extensive earlier pilot studies and animal evidence (aged mice, HIV premature aging), (4) clear, well-characterized mechanism (GSH precursor delivery), (5) reasonable safety profile across studies.
LIMITED BY: single-research-team evidence base (Sekhar lab dominates; need independent replication), modest sample size in pivotal RCT (n=24 receiving treatment), limited duration (16 weeks max), aging hallmarks improvements need longer follow-up to assess durability. SAFETY: Generally well-tolerated with no significant adverse effects in trials. Best positioned as: (a) HEALTHSPAN / LONGEVITY SUPPLEMENT for adults 50+ years interested in aging research-based interventions, (b) MITOCHONDRIAL SUPPORT for those with fatigue or metabolic concerns related to aging, (c) GLUTATHIONE RESTORATION for those interested in antioxidant capacity, (d) ADJUNCT for metabolic syndrome/insulin resistance management (HOMA-IR improvement supportive), (e) functional improvement target (gait speed, strength) in older adults concerned about physical decline.
Honest framing: among the most promising 'longevity' supplements with HUMAN RCT evidence (vs preclinical-only NMN, NR, etc.) — but the evidence base is dominated by one research team and warrants independent replication. The mechanism is biochemically sound and the magnitude of effects in Sekhar's trial is substantial. Reasonable evidence-based bet for adults concerned about aging-related declines, with appropriate epistemic humility about single-team replication.